Analyzing Costs Per Clinical Remission of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in Rheumatoid Arthritis from a Public Perspective in Brazil
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.2217
https://www.valueinhealthjournal.com/article/S1098-3015(13)04129-6/fulltext
Title :
Analyzing Costs Per Clinical Remission of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in Rheumatoid Arthritis from a Public Perspective in Brazil
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)04129-6&doi=10.1016/j.jval.2013.08.2217
First page :
A716
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2033